The multi-functional role of sphingosylphosphorylcholine

来自 : 发布时间：2024-05-17

ActionsCite Favorites Display options Display options Format 1 School of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. g.f.nixon@abdn.ac.uk 1 School of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. g.f.nixon@abdn.ac.uk The sphingomyelin metabolite, sphingosylphosphorylcholine (SPC) has been the subject of much recent interest and controversy. Studies have indicated that SPC naturally occurs in plasma and a constituent of lipoproteins. Synthesis is also increased in some pathological conditions. Research has demonstrated that SPC is a potentially important lipid mediator of cell type specific functions in major tissues, such as heart, blood vessels, skin, brain and immune system. These effects are regulated via a number of different intracellular signalling cascades, also dependent upon cell type. Initial reports identifying high affinity SPC receptors at first appeared to reinforce the physiological relevance of this sphingolipid. However, these studies have now been retracted. Some SPC effects have been shown be occur via plasma membrane receptors for the related sphingolipid, sphingosine 1-phosphate (S1P). Despite a lack of well-defined receptor signal transduction mechanisms and sparse pharmacological data, several key characteristics of SPC are now emerging. SPC can act as a mitogen in several different cell types and in certain circumstances, may also be a pro-inflammatory mediator. In this review, these actions of SPC are discussed with a view to understanding the potential physiological relevance of this sphingolipid. Choi SK, et al. Cardiovasc Res. 2009 May 1;82(2):324-32. doi: 10.1093/cvr/cvp054. Epub 2009 Feb 13. Cardiovasc Res. 2009. PMID: 19218288 Mulders AC, et al. Auton Autacoid Pharmacol. 2007 Oct;27(4):173-9. doi: 10.1111/j.1474-8673.2007.00410.x. Auton Autacoid Pharmacol. 2007. PMID: 18076478 Lee HY, et al. Acta Pharmacol Sin. 2006 Oct;27(10):1359-66. doi: 10.1111/j.1745-7254.2006.00426.x. Acta Pharmacol Sin. 2006. PMID: 17007744 Hemmings DG. Naunyn Schmiedebergs Arch Pharmacol. 2006 Apr;373(1):18-29. doi: 10.1007/s00210-006-0046-5. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16570136 Meyer zu Heringdorf D, et al. Biochim Biophys Acta. 2002 May 23;1582(1-3):178-89. doi: 10.1016/s1388-1981(02)00154-3. Biochim Biophys Acta. 2002. PMID: 12069827 Ma J, et al. Parasitol Res. 2021 Jul 5. doi: 10.1007/s00436-021-07222-8. Online ahead of print. Parasitol Res. 2021. PMID: 34219189 Lee HY, Cho KM, Kim MK, Lee M, Kim H, Choi CY, Kim KK, Park JS, Kim HH, Bae YS. Lee HY, et al. J Cell Mol Med. 2021 Jan;25(1):473-483. doi: 10.1111/jcmm.16101. Epub 2020 Nov 23. J Cell Mol Med. 2021. PMID: 33230972 Free PMC article. Yoon SB, Lee CH, Kim HY, Jeong D, Jeon MK, Cho SA, Kim K, Lee T, Yang JY, Gong YD, Cho H. Yoon SB, et al. J Inflamm (Lond). 2020 May 29;17:20. doi: 10.1186/s12950-020-00244-6. eCollection 2020. J Inflamm (Lond). 2020. PMID: 32514255 Free PMC article. Allende G, Chávez-Reyes J, Guerrero-Alba R, Vázquez-León P, Marichal-Cancino BA. Allende G, et al. Front Pharmacol. 2020 May 8;11:628. doi: 10.3389/fphar.2020.00628. eCollection 2020. Front Pharmacol. 2020. PMID: 32457622 Free PMC article. Review. Park MK, et al. Cancers (Basel). 2019 Oct 31;11(11):1696. doi: 10.3390/cancers11111696. Cancers (Basel). 2019. PMID: 31683697 Free PMC article. Review.